AC Immune SA today announced that its collaboration partner Genentech, a member of the Roche group, has dosed the first patient in a Phase 1 clinical trial for Alzheimer’s disease with an anti-Tau monoclonal antibody. This product candidate was discovered and humanized in collaboration between AC Immune and Genentech. Upon commencement of the Phase 1 clinical trial, AC Immune became eligible to receive a milestone payment of CHF14 million, which is expected to be paid in the third quarter of 2016. This will be the second milestone payment under the 2012 collaboration and licensing agreement with Genentech for anti-Tau antibodies for the treatment of Alzheimer’s disease and other neurodegenerative diseases.
Source: AC Immune
I believe this is one of the such a lot vital info for me.
And i’m glad studying your article. However wanna statement on some general issues,
The site taste is wonderful, the articles is actually excellent : D.
Good process, cheers